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SUMMAry – treatment of locally advanced prostate cancer (pC) represents a challenge before 
multidisciplinary team (Mdt), typically includes not only local disease control but also systemic 
therapy and it should be tailored to each individual patient. We present a case of a 58-year-old man, 
whose pC presented itself as a locally advanced disease. Bearing in mind the patients’ age, absence of 
comorbidities but also his preferences, Mdt decided that the rational first step in almost imminent 
multimodal treatment should be radical prostatectomy (rp). due to several local adverse factors (pos-
itive surgical margins, extracapsular extension, seminal vesicle involvement) on rp specimen patho-
histology and postoperative prostate specific antigen (pSA) of 6.69 ng/ml our Mdt determined lu-
teinizing hormone-releasing hormone (lHrH) agonist therapy in the course of 3 years plus immedi-
ate salvage radiotherapy. The therapy was well tolerated, although there was one episode of transitory 
radiation cystitis roughly one year after its completion. After 45 months of follow-up the patient is 
without signs of biochemical recurrence of pC, with fully restored testosterone level and good quality 
of life. The main task in advanced pC management, through multidisciplinary approach, is providing 
good oncological outcome while trying to reduce treatment morbidity and to maintain a good quality 
of life.
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Introduction
prostate cancer (pC) is the second most common 
malignancy in men1,2, but it is not a universal entity, 
with clinical behavior spanning from indolent, slowly 
progressive disease to aggressive, life-threatening con-
dition1,3, so the treatment should be tailored to specific 
circumstances of each individual situation/patient. 
Management of high-risk localized and locally ad-
vanced pC is a difficult task and should include a mul-
tidisciplinary approach in trying to find the right 
treatment modalities and their sequencing, while at 
the same time avoiding treatments’ side effects as much 
as possible. Therefore the „burning” questions on ad-
vanced pC management are discussed biennially at the 
Advanced prostate Cancer Consensus Conference 
(ApCCC)4. By the european Association of Urology 
(eAU) risk group classification1 pC is defined as lo-
cally advanced in case of ct3-4 or cn+ disease and any 
prostate specific antigen (pSA) level and gleason 
score (gS). treatment of locally advanced pC usually 
includes combination of both local and systemic ther-
apy, where radical prostatectomy (rp) with extended 
pelvic lymph node dissection (elnd) can be per-
formed in selected patients as a first step in multimod-
al treatment (which also includes adjuvant or salvage 
radiotherapy, androgen deprivation therapy [Adt] 
and more)1. Here we present a case of a man with lo-
B. Sudarević Management of locally advanced, aggressive prostate cancer
Acta Clin Croat, Vol. 58, (Suppl. 2) 2019 85
cally advanced disease, who received multimodal treat-
ment of pC at the departments of Urology and on-
cology in osijek University Hospital from 2016 to 
2019.
Case Report
A 58-year-old man was referred to our outpatient 
clinic by his general practitioner because of an elevated 
pSA level of 39 ng/ml (repeated pSA test). The pSA 
screening was initiated by a physician due to patients’ 
age alone, since the patient had no lower urinary tract 
symptoms (lUtS) or other urological problems. He 
was an ex-smoker, with no other chronic diseases and 
with good health and performance status. on digital 
rectal exam (dre) the prostate was initially enlarged, 
painless and inconspicuous, albeit with subtle hard-
ened consistency in general. There were no clinical or 
laboratory findings that would suggest a urinary tract 
infection so the patient was scheduled for an outpa-
tient transrectal prostate biopsy. The procedure went 
uneventful, while the pathohistological finding re-
vealed gS 4+3=7 adenocarcinoma of the prostate (in-
ternational Society of Urological pathology grade 3), 
with 10 out of 12 biopsy cores positive for cancer. We 
proceeded with a diagnostic evaluation: bone scintig-
raphy revealed no metastases and the abdominopelvic 
computed tomography (Ct) scan showed only slight-
ly enlarged prostate (32 g) that was mildly inhomoge-
neous on native and postcontrast study. furthermore, 
Ct scan identified three perivesical lymph nodes, the 
largest being 9 millimeters in diameter. At that time, it 
was not technically possible to perform multiparamet-
ric magnetic resonance imaging (mp-Mri) of the 
prostate at our hospital, so we were rather deprived of 
adequate local staging. The patient was presented at 
the uro-oncological multidisciplinary team (Mdt) at 
the department of Urology and it was concluded that 
rp was the treatment of choice, which was also in line 
with patients’ preferences. rp was performed in feb-
ruary 2016 and the procedure, as well as the early post-
operative course went uneventful. patient was dis-
charged on the sixth postoperative day, while on the 
fourteenth day the outpatient cystography was per-
formed and revealed no urine leakage. The urethral 
catheter was removed and afterwards the patient uri-
nated normally. pathohistologically, prostate of 75 g 
was 90 % infiltrated with tumor tissue, with the largest 
tumor nodus of 35 x 15 mm. The tumor was composed 
of acinar and mucinous (colloid) subtypes of prostate 
adenocarcinoma. There was an upgrading of the initial 
biopsy gS of 7 to definitive gS of 4+4=8. There were 
several local adverse factors: extracapsular extension, 
bilateral seminal vesicle involvement and multifocal 
and bilateral positive surgical margins. There was also 
perineural invasion present, but without lymphovascu-
lar invasion. from 3 examined lymph nodes, one was 
infiltrated with tumor tissue.
Six weeks after rp the patient was well and had 
regained full recovery of urinary continence. Consid-
ering postoperative pSA of 6.69 ng/ml and adverse 
pathologic features of rp specimen, our uro-oncolog-
ical Mdt decided to start luteinizing hormone-re-
leasing hormone (lHrH) agonist therapy with 
3-month formulation of goserelin (which was contin-
ued for 3 years overall, from April 2016 until January 
2019) and salvage radiotherapy of the prostatic bed 
plus whole pelvis was initiated in June 2016, where pa-
tient was treated to a dose of 66 gy in 33 fractions. 
radiotherapy was well tolerated and in october 2016 
pSA was 0.02 ng/ml, with castration testosterone level 
as the lHrH agonist therapy was continued.
in May 2017 the patient presented himself with 
gross hematuria and subsequently underwent outpa-
tient urethrocystoscopy which revealed a shallow, ir-
regular, ulcer-like lesion on the posterior bladder wall, 
15 mm in diameter, without the presence of active 
bleeding. The clinical suspicion of postirradiation le-
sion was confirmed pathohistologically at an inpatient 
bladder biopsy, as there were histopathological features 
of inflammation, with no sign of malignancy and with 
negative urine cytology. Hematuria had not recurred, 
and patients’ voiding was normal afterwards.
Hereafter, oncological and urological surveillance 
was continued, with lHrH therapy every three 
months until January 2019 when the therapy was con-
cluded with twelfth lHrH agonist administered and 
with a pSA of 0.0 ng/ml and testosterone level of 0.36 
nmol/l. After the cessation of lHrH agonist therapy 
the patients’ testosterone level was fully restored. 
Meanwhile, a cardiological evaluation was carried out 
and the patient was suitable for erectile dysfunction 
therapy with sildenafil. His last checkup was in Sep-
tember 2019, still with undetectable pSA and without 
micro- or macro-hematuria and he was scheduled for 
the next control in six months.
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Discussion
opportunistic screening or early detection of pC 
has been increasingly used in Croatia (e.g. pSA testing 
is performed during regular yearly checkup of war vet-
erans of Croatian War of independence), even though 
population screening is not introduced by health au-
thorities. The topic of mass screening is globally con-
troversial5,6,7 and not recommended by the eAU1 as it 
had not led to a decrease in pC mortality, which is the 
main endpoint in pC diagnosis and treatment. How-
ever, opportunistic screening in the case of our patient 
has certainly resulted in a timely diagnosis and con-
secutive treatment of what proved to be an aggressive 
disease.
We performed systemic transrectal prostate biopsy 
without previous mp-Mri of the prostate which is an 
acceptable approach according to eAU guidelines1. 
nevertheless, 2019 edition of eAU guidelines recom-
mend performing prostate mp-Mri before first biop-
sy if possible1,8. in the beginning of 2016 mp-Mri was 
not available in our institution and when it became 
available the practice was to use it prior to a planned 
repeat biopsy and not in biopsy-naïve patients. Un-
availability of mp-Mri at the time was also the reason 
for not performing it in local staging prior to rp.
After the histopathological confirmation of pC, 
and according to pSA value and gS, we carried out 
abdominopelvic Ct and bone scintigraphy for meta-
static screening. Bone scan was unremarkable and 
without metastatic spread while Ct scan revealed 
three perivesical lymph nodes, the largest being 9 mil-
limeters in diameter. The usual lymph node size 
threshold for lymph nodes in the pelvis suspicious for 
metastasis is 8 mm1,9 which could classify the disease 
in our patient as locally advanced (n+) and not high-
risk localized pC. The patient was presented at Hospi-
tals’ uro-oncological Mdt which concluded that de-
spite our risk-group stratification dilemma the reason-
able first step in his treatment should be rp with ex-
tended pelvic lymph node dissection (elnd), 
especially considering his young age and absence of 
comorbidity. The procedure and early postoperative 
period went uneventful, but the local adverse factors 
(extracapsular extension, bilateral seminal vesicle in-
volvement and multifocal and bilateral positive surgi-
cal margins) on histopathological specimen, as well as 
high postoperative pSA, necessitated further onco-
logical treatment. There were also only three lymph 
nodes removed which does not qualify as elnd. in 
ApCCC 20174 there was a panel question on the ad-
equate number of lymph nodes removed during elnd 
and 49 % of experts answered 11-19, while 27 % con-
sidered 20 lymph nodes or more as adequate sampling. 
While we failed to provide important staging infor-
mation with elnd, it does not, though, influence the 
overall oncological outcome10.
Adt was initiated and the patient underwent sal-
vage 3d conformal radiotherapy (3d-Crt) of the 
prostatic bed and whole pelvis. intensity-modulated 
radiotherapy (iMrt) and volumetric arc external-
beam radiotherapy (vMAt), which are a gold stan-
dard for external-beam radiotherapy (eBrt)1, were 
only later introduced at our institution. There were no 
early complications of eBrt but roughly one year af-
ter its completion the patient presented himself with 
hematuria and ulcer-like bladder lesion which proved 
to be inflammatory postirradiation consequence rather 
than metachronous transitional cell carcinoma of the 
bladder. in further course, after three years of Adt the 
treatment was completed and shortly thereafter the 
patients’ testosterone level was fully restored, and he 
was without signs of biochemical recurrence after 45 
months of follow-up.
in conclusion, the treatment of pC, especially lo-
cally advanced disease represents a challenge. Bearing 
in mind that pC is not a unique clinical entity, each 
patient should have his treatment tailored individually 
and based upon up-to-date scientific evidence. pa-
tients’ preferences, age and performance status, as well 
as advantages and shortcomings of treatment modali-
ties should be taken into consideration when deciding 
upon certain pC therapeutic route. The goal of pC 
treatment is not only in achieving a good oncological 
outcome but also in reducing treatment morbidity and 
maintaining a good quality of life, where reduction of 
overdiagnosis and overtreatment plays a crucial role. 
Mdt assessment reduces the possible bias of one spe-
cialist decision-making in every oncological disease, 
and thus in pC as well.
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Sažetak
liJeČenJe loKAlno UZnApredovAlog, AgreSivnog KArCinoMA proStAte  
– priKAZ SlUČAJA
B. Sudarević
liječenje lokalno uznapredovalog karcinoma prostate (pC) predstavlja izazov za multidisciplinarni tim (Mdt), najčešće 
uključuje kombinaciju lokalne kontrole bolesti i sustavnog liječenja te bi trebalo biti prilagođeno svakom pojedinom bolesni-
ku. prikazujemo slučaj 58-godišnjeg bolesnika čiji se pC očitovao kao lokalno uznapredovala bolest. Uzimajući u obzir bole-
snikovu dob, odsutnost komorbiditeta, ali i njegove želje, Mdt je odlučio kako bi prvi korak u gotovo sigurno multimodal-
nom liječenju trebala biti radikalna prostatektomija (rp). Zbog brojnih nepovoljnih lokalnih čimbenika (pozitivni kiruški 
rubovi, ekstrakapsularno širenje i zahvaćenost sjemenih mjehurića) na patohistološkom preparatu nakon rp-a i zbog post-
operativnog prostata specifičnog antigena (pSA) od 6,69 ng/ml naš Mdt je odlučio provesti liječenje agonistima hormona 
oslobađanja luteinizirajućeg hormona (engl. luteinising hormone-releasing hormone; lHrH) kroz 3 godine te neodgođenu 
salvage radioterapiju. Bolesnik je liječenje dobro podnio, premda se otprilike godinu dana nakon završetka radioterapije po-
javila prolazna epizoda radijacijskog cistitisa. Bolesnik je bez znakova aktivne bolesti nakon 45 mjeseci praćenja, dobre kva-
litete života i potpuno oporavljene serumske razine testosterona. glavni cilj liječenja uznapredovalog pC-a, uz multidiscipli-
narni pristup, jest postići dobar onkološki ishod, ali i smanjiti morbiditet liječenja na najmanju moguću mjeru te održati 
kvalitetu života dobrom.
Ključne riječi: Neoplazme prostate; Gonadotropin-oslobađajući hormon; Radioterapija; Disekcija limfnih čvorova
